Vol. 1 No. 6 (2026), Articles
Vol. 1 No. 6 (2026)

Molecular and Cellular Mechanisms of Epidermal Barrier Dysfunction and Targeted Microbiome Modulation in Eczematous Process

Articles
Published 2026-06-11
SHOKHINOVA ANAKHITA
1st-year Resident Physician Samarkand State Medical University, Samarkand, Republic of Uzbekistan
SHARIPOVA SABINA
1st-year Resident Physician Samarkand State Medical University, Samarkand, Republic of Uzbekistan
PDF

Keywords

Eczema, epidermal barrier, filaggrin, skin microbiome, Staphylococcus aureus, interleukin-13, transepidermal water loss (TEWL), targeted therapy.

How to Cite

SHOKHINOVA ANAKHITA, & SHARIPOVA SABINA. (2026). Molecular and Cellular Mechanisms of Epidermal Barrier Dysfunction and Targeted Microbiome Modulation in Eczematous Process. KLINIK VA FUNDAMENTAL TIBBIYOT TADQIQOTLARI JURNALI, 1(6), 20-25. https://innopublication.com/index.php/jcmfr/article/view/762
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The article reviews modern concepts of the etiopathogenesis of eczema (atopic dermatitis) from the perspective of the synergistic interaction of genetic, microbiological, and immunological factors. The authors present the results of a clinical and laboratory study evaluating the state of the lipid barrier, transepidermal water loss (TEWL) levels, and the qualitative composition of the skin microbiome in patients during the acute phase. The study demonstrates the pivotal role of Staphylococcus aureus hypercolonization and filaggrin deficiency in maintaining chronic Th2-mediated inflammation. Furthermore, it substantiates the efficacy of incorporating modern topical agents formulated with bacterial lysates as well as targeted biological drugs into the comprehensive management of the disease.

PDF

References

1. Bieber, T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.Nature Reviews Drug Discovery.2022;21(1):21-40.

2. Paller, A. S., Kong, H. H., Seed, P., et al. The microbiome in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology. 2019;143(1):26-35.

3. Elias, P. M., Wakefield, J. S. Mechanisms of abnormal epidermal barrier function in atopic dermatitis.Dermatologic Clinics. 2017;35(3):337-343.

4. Langan, S. M., Irvine, A. D., Weidinger, S. Atopic dermatitis. The Lancet. 2020;396(10247):345-360.

5. Byrd, A. L., Belkaid, Y., Segre, J. A. The human skin microbiome. Nature Reviews Microbiology. 2018;16(3):143-155.

6. Irvine, A. D., McLean, W. I., Leung, D. Y. Filaggrin mutations associated with skin and allergic diseases. New England Journal of Medicine. 2011;365(14):1315-1327.

7. Guttman-Yassky, E., Waldman, A., Ahluwalia, J., et al. Atopic dermatitis: pathogenesis. Seminars in Cutaneous Medicine and Surgery. 2017;36(3):100-103.

8. Leung, D. Y. M., Guttman-Yassky, E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment. Journal of Allergy and Clinical Immunology. 2014;134(4):769-779.

9. Geoghegan, J. A., Irvine, A. D., Foster, T. J. Staphylococcus aureus and atopic dermatitis: a complex interaction. Trends in Microbiology. 2018;26(6):484-497.

10. Simpson, E. L., Chalmers, J. R., Hanifin, J. M., et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology. 2014;134(4):818-823.

11. Werfel, T., Allam, J. P., Biedermann, T., et al. Cellular immunology of eczema. Chemical Immunology and Allergy. 2014;100:159-167.

12. Nakatsuji, T., Chen, T. H., Two, A. M., et al. Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger vascular permeability and inflammation. Journal of Investigative Dermatology. 2016;136(11):2192-2200.

13. Thijs, J. L., Strickland, I., Bruijnzeel-Koomen, C. A., et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Current Opinion in Allergy and Clinical Immunology. 2015;15(4):353-360.

14. Flohr, C., Mann, J. New insights into the epidemiology of childhood eczema. Allergy. 2014;69(1):3-16.

15. Czarnowicki, T., He, H., Krueger, J. G., Guttman-Yassky, E. Atopic dermatitis endotypes and implications for targeted therapeutics. Journal of Allergy and Clinical Immunology. 2019;143(1):1-11.

16. Weidinger, S., Novak, N. Atopic dermatitis. The Lancet. 2016;387(10023):1109-1122.

17. Brunner, P. M., Guttman-Yassky, E., Leung, D. Y. The immunology of atopic dermatitis and its therapeutic implications. Journal of Allergy and Clinical Immunology. 2017;139(4):S65-S76.

18. Kim, J., Kim, B. E., Leung, D. Y. Pathophysiology of atopic dermatitis: Clinical implications. Allergy and Asthma Proceedings. 2019;40(2):84-92.

19. Silverberg, J. I. Public health burden and epidemiology of atopic dermatitis. Dermatologic Clinics. 2017;35(3):283-289.

20. Gandhi, N. A., Bennett, B. L., Graham, N. M., et al. Targeting key cytokines in eczema: the clinical development of dupilumab. Nature Reviews Drug Discovery. 2016;15(1):35-50.